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Abstract
Background—Advances in DNA sequencing technology have resulted in an abundance of 
personalized data with challenging clinical utility and meaning for clinicians. This wealth of data 
has potential to dramatically impact the quality of healthcare. Nurses are at the focal point in 
educating patients regarding relevant healthcare needs; therefore, an understanding of sequencing 
technology and utilizing these data are critical.
Aim—The objective of this paper is to explicate the role of nurses and nurse scientists as integral 
members of healthcare teams in improving understanding of DNA sequencing data and 
translational genomics for patients.
Approach—A history of the nurse role in newborn screening is used as an exemplar.
Discussion—This paper serves as an exemplar on how genome sequencing has been utilized in 
nursing science and incorporates linkages of other omics approaches used by nurses that are 
included in this special issue. This special issue showcased nurse scientists conducting multi-omic 
research from various methods, including targeted candidate genes, pharmacogenomics, 
proteomics, epigenomics and the microbiome. From this vantage point, we provide an overview of 
the roles of nurse scientists in genome sequencing research and provide recommendations for the 
best utilization of nurses and nurse scientists related to genome sequencing.
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Nurses are uniquely qualified to examine and understand patient reports based on DNA 
sequencing and to translate genomic information to patients and their families which can 
dramatically improve health outcomes. Recent advances have made it economically and 
technically feasible to employ high throughput DNA sequencing to identify potentially life-
changing or life-altering therapies for individuals at high risk for illnesses with a strong 
underlying genetic basis. However, the path between raw sequence data and direct clinical 
utility presents a significant challenge. Content within this special issue includes examples 
of how nurses are working to bridge the gap from omics research results to clinical 
application.
DNA sequencing technologies are already in routine use in the clinic, and nurses play a 
crucial role in turning genetic information into concrete action plans for their patients. In the 
coming years the onslaught of information which will be reaching the bedside and the clinic 
will become a literal tidal wave. In order to give the best care possible to their patients, 
nurses need to understand this crucial information extremely well and be adequately 
prepared to support patients and families in using the new information to bring about the 
best possible patient care outcomes. Additionally, it is imperative that nurses consider how 
the omics data deluge will influence nursing research in order to develop new knowledge 
relevant to nursing practice. This paper will show how genome sequencing has been utilized 
in nursing science and will incorporate linkages other omics approaches used by nurses that 
are included in this special issue. This Nursing Research special issue on Omics in Nursing 
Science showcases nurse scientists conducting multi-omic research from various methods 
such as targeted candidate genes (Correa-Rodriguez, Rio-Valle & Blanca, 2017; Zahari et 
al,. 2017; Smoot et al., 2017; Han et al., 2017; Gillespie et al., 2017; Lin, Nunez, Johns & 
Shaio, 2017; Gonzales, Yu, & Shaio, 2017), pharmacogenomics (Aroke, Crawford, Dungan, 
2017), proteomics (Voss, et al., 2017), epigenomics (Braid, Okrah, Shetty & Bravo, 2017), 
and the microbiome (Cong et al., 2017; Jordan et al., 2017; Ames, Ranucci, Moriyama & 
Wallen, 2017), and lastly, we provide an overview of the role of nurse scientists in genome 
sequencing here in this paper. We hope to inspire nurses to continue utilizing innovative 
omics approaches in their research, consider where the field of nursing research may be 
heading, and envision the use of multi-omic strategies as the basis for development of useful 
interventions and subsequent translation for nursing practice in the US and abroad.
Newborn Screening— A Framework for Genome Based Population 
Screening
Population-based genetic screening has great potential to improve health outcomes for 
individuals and health care costs for society. A striking example exemplifying this concept is 
mandated newborn screening, most of which involves testing the blood of newborns blood to 
identify disorders that are not readily observable upon physical exam shortly after birth 
(Association of Women’s Health, Obstetric and Neonatal Nurses [AWHONN], 2010; Berry, 
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2015). Newborn screening is known to bring great benefit to children and is considered 
without question to be cost effective in our current era of healthcare cost management 
(Centers for Disease Control and Prevention, 2008; Geelhoed, Hounsome & O’Leary, 2005). 
Newborn screening, which includes screening for various genetic disorders, is currently a 
standard of care and reimbursed in all 50 US states as well as many other countries around 
the world. The impact and value of newborn screening in the improvement of health care 
outcomes in populations around the world is without question due to the improved quantity 
and quality of lives of the infants identified with conditions that require early treatment for 
healthy development.
A brief review of the history of newborn screening and the roles nurses play in delivering 
life changing and life-saving care is instructive. Newborn screening first began in the 1950s 
based on a growing understanding of phenylketonuria (PKU), an inborn error in metabolism 
(Paul & Brosco, 2013). This autosomal recessive disorder that results in decreased levels of 
they enzyme that converts phenylalanine to tyrosine and affects approximately 1 in 15,000 
children in the US. The enzyme deficiency present in individuals with PKU was first 
elucidated in the 1930s in Norway. By the 1950s research had led to the suggestion that a 
strict limitation on the amount of phenylalanine in the diet could completely reverse the 
effects of the genetic mutation. However, in order to be effective in preventing detrimental 
effects related to the enzyme deficiency this dietary based therapy must begin as soon after 
birth as possible. Furthermore, the dietary change could not simply eliminate phenylalanine 
from the diet since this amino acid is essential for life but rather provide the child with a diet 
very low in phenylalanine but adequate to allow normal amounts of protein synthesis. In the 
1950s, a test for identifying infants with PKU using ferric chloride which reacts to the urine 
in a baby’s diaper was put into use. This test allowed infants with PKU to be identified 
shortly after birth in order to evaluate the effectiveness of early dietary intervention for PKU 
(Groves & Scholesser, 1964; Ragsdale & Koch, 1964).
Nurses are integral to the interdisciplinary teams that work with families for the 
implementation of this life changing intervention (Steele, 1989). The low phenylalanine diet 
was an intervention that did not fix everything in a single visit to the office but rather 
required the regular and engaged interaction between parents and their healthcare providers 
over the course of the entire growth to maturity of the child. The nurse was a pivotal player 
in the team supporting the family in efforts to save the child from serious brain damage. As 
dietary intervention proved to be so completely successful in PKU, it soon became a 
mainstay in nursing education for students to gain an intimate understanding of PKU and its 
therapy. As time moved on more efficient methods of screening for PKU were developed. 
For some period of time the innovation that changed newborn screening methods was a test 
based on bacterial growth that would allow the estimation of phenylalanine levels from a 
drop a blood from a heelstick on a filter paper disc. This “Guthrie card” method of screening 
newborns (named after the innovator of the bacterial growth test) soon became standard of 
care. Additional inborn errors in metabolism with corresponding effective interventions 
could be detected by the bacterial growth assay, but the next significant breakthrough came 
with the implementation of mass spectrometer based readouts from the Guthrie card. Now, a 
large number of metabolites could be quantitated in a single rapid and automated reading 
procedure. The number of tests that could now be read by a centralized laboratory and an 
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automated report generated numbered in the tens or even hundreds of thousands per year. 
The impact of this discovery at point-of-care of this expansion were substantial. Nurses, are 
and have been critical in the counseling and teaching functions of providing parents with 
guidance and a resource in providing this form of positive health benefit were faced with an 
increasing challenge of diseases to become familiar with and therapeutic interventions to 
understand and develop. It is the multiplication of these challenges beyond the current form 
of newborn screening that we believe nurses will need to meet in the coming years. The 
reasons these new forms of information, intervention and therapy will without question enter 
the healthcare arena are based on the principles that currently guide newborn screening.
The principles which underlie newborn screening are that health providers bear a 
responsibility to identify and make available interventions which are life saving or may 
substantially improve the lives of infants with disorders detected through newborn screening. 
The first criterion that must be met for a condition to be included in a newborn screening 
panel is that the condition must be actionable (i.e., a definitive positive test result is directly 
associated with a clinical intervention that extends life and/or substantially improves the 
health of the infant). Beyond this basic principle there is considerable variability in the 
number of disorders tested for, how long samples are kept, and protocol for disseminating 
results. The protocols for each of these issues vary on a state-by-state basis in the US (see 
Table 1; Supplemental Digital Content 1) and a country-by-country basis worldwide.
There is now a burgeoning movement to incorporate whole-genome sequencing methods, 
which reads the entire genome of an individual, into the newborn screening process. 
Sequencing technologies that read small regions of an individual’s genome are already used 
for confirmatory and follow-up testing related to positive or ambiguous results from initial 
mass spectrometer based screening. Assessment of the analytic performance of using 
sequencing technologies as the initial screening test has determined results are comparable 
to mass spectrometry with fewer false positive (Baker et al., 2016; Bodian et al., 2016).
Testing for small molecules, such as proteins or other metabolites, created an economically 
feasible way to screen for many conditions at once because technology (mass spectrometry) 
detects molecules produced by targeted conditions (e. g., PKU, maple syrup disease). This 
testing format allows screening a group of conditions together, but would not be 
economically justified to screen only one at a time. Screening in newborns or at the 
population level in adults based on DNA sequencing has not been feasible until recently due 
to the relatively high cost. However, the cost of sequencing technologies has dramatically 
decreased (Figure 1) (Wetterstrand, 2015); several ongoing studies are focused on 
determining the best way to incorporate these approaches into standard care across the 
lifespan (www.genomes2people.org/g2p/). Since there is broad applicability across the 
lifespan, these technologies will be able to improve our understanding of etiology and care 
for both common and rare diseases. For example, cardiovascular disease occurring 
consequential to partial loss of function in the LDL receptor gene is estimated to have a 
frequency of 1 in 200 individuals, which is relatively common, and has a well-established 
therapeutic intervention (prescription of pharmacologic therapies such as use of statins or 
other medications based on an individual’s unique genomic profile) could be clearly 
identified and treated earlier. Sequencing technologies will also drive the identification of 
Taylor et al. Page 4
Nurs Res. Author manuscript; available in PMC 2018 March 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
relatively rare but nevertheless life threatening conditions such as familial 
hypercholesterolemia (Wright, Housman & Taylor, 2016) and familial hemophagocytic 
lymphohistocytosis, for example.
For these reasons, as the cost of sequencing continues to drop and the rationale for it 
continues to become more and more compelling, we believe that whole genome sequencing 
for screening and diagnostic purposes will become routine. Sequencing data will make a 
dramatic difference in the choice of therapeutic intervention appropriate to treat or forestall 
serious negative health outcomes. Nurses will often be implementing therapeutic 
interventions derived from sequence information from a genetic screening test. A strong 
understanding of the connection between the sequencing result and the individuals therapy 
based on that sequencing result will be essential for the most effective nurse-provided care 
and support for patients.
The International Society of Nurses in Genetics (ISONG) (International Society of Nurses in 
Genetics, 2012) issued a position statement on the role of nurses in the newborn screening 
process in 2012, which recommends the following for nursing:
• Active participation in current knowledge of NBS as an advocate for patients and 
families,
• Provide patient education prior to testing for NBS,
• Offer counseling to families post testing,
• Explain use of results, and if being utilized in research studies, explain their 
benefits, and
• Include information about NBS in newborn care curriculum for patient 
education.
We have adapted key features of the ISONG newborn screening position statement to 
propose how nurses and nurse scientists can broadly utilize DNA sequencing technology, 
participate in policy development, translate findings obtained from these methods, and 
ensure adequate education and dissemination of information to patients and the public 
(Figure 2). Nurses have the knowledge and skills to be involved with clinical care that 
incorporates results from sequencing technologies, and must stay abreast of new 
developments to provide competent care for diverse patient populations. First, we must 
incorporate advances into nursing curricula so that clinical nurses and nurse scientists have 
the knowledge to develop and incorporate innovative interventions into practice to improve 
or maintain patient health. Ideally, there will be an exchange of information between nurse 
clinicians and nurse scientists so that new knowledge can be generated to serve patients most 
in need. For example, individuals of African Ancestry in the US suffer disproportionately 
from poor cardiovascular outcomes. Familial hypercholesterolemia is a genetic condition 
that can result in severe dysfunction at an early age. However, many of the genetic variants 
that have been identified are not present in patients of African ancestry and much of the 
sequencing research to date has been conducted in populations of European ancestry 
(Wright, Housman, & Taylor, 2016). Communication between clinicians and researchers 
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will be vital in areas such as these to identify disease variants that are not consistent to 
realize the true potential of personalized medicine.
The Current Policy Landscape
Currently, there are two policy statements intended to establish guidelines for testing and 
reporting genome sequencing results to patients in the clinical setting. First, the American 
College of Medical Genetics and Genomics (ACMG Board of Directors, 2014; Green et al., 
2013) recommended that testing be conducted by a trained healthcare professional. 
Additionally, when whole genome sequencing is conducted, patients must be clearly 
informed about all “actionable” variants that are tested, and the opportunity to opt out of this 
testing is provided (for both adults and children). (Actionable variants are mutations that are 
deleterious to health and have specific, evidence-based recommendations that can be 
implemented to improve health outcomes in the affected individual.) Currently, guidance on 
how and whether “incidental” or “secondary” findings should be reported remains 
ambiguous. A second statement on genome sequencing published by the Association of 
Genetic Nurses and Counsellors (AGNC) in the United Kingdom and Ireland (Middleton et 
al., 2014) is harmonious with the ACMG statement, but takes the issue of incidental findings 
a step further. Two striking differences between the statements are : (a) the AGNC refers to 
genome sequencing screening as “opportunistic” and cautions that screening should be done 
when benefits are judged to outweigh harms, and (b) the AGNC does not recommend 
screening children for ”adult onset” diseases.
As nurse scientists and genetic counselors consider the use of genome sequencing in clinical 
and community settings, it is important to consider the usefulness of this technology as a 
screening tool and how it has been used in the past to identify heritable disorders in 
programs such as prenatal screening. In 2012, the Genomic Nursing State of the Science 
Advisory Panel was held at the National Institutes of Health and made recommendations 
that research should focus on building capacity for using genomic information in a clinically 
meaningful way to reduce costs and improve health outcomes in diverse patient populations 
(Calzone et al., 2013).
Additionally, there is an increasing demand from the public for information regarding 
genetic predisposition for disease. However, the reliability, accuracy, and clinical 
manifestations associated with genetic variants identified by whole genome sequencing 
remain largely unknown because research studies focused on affected individuals do not 
evaluate population-based data or individuals with the variant who are unaffected (Williams, 
Cashion, & Veenstra, 2015). As public policy statements evolve, the practical implications of 
new developments in DNA sequencing for nurses will include the need to keep curricula in 
nursing education programs up-to-date (Calzone et al., 2013; Conley et al., 2015) as new 
sequencing and therapeutic modalities based on this screening are brought into practice 
(Wright, Housman & Taylor, 2016). For nurses already in practice, it is critical that in-
service education programs be made available so that nurses will have useful resources to 
integrate the new information into their day-to-day nursing activities effectively.
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Clear, effective and ethical communication of the relevance and impact of the results of these 
technologies is the most significant barrier to development of potentially life-saving 
therapeutic intervention strategies and dramatic overall improvements in health. Nurses 
should also be aware of the classification categories put out by the AMCG on how to 
interpret sequence variant data and the decision tree for use of these data in clinical care 
(Richards et al., 2008; Richards et al., 2015) (Table 2). Once DNA sequence variants are 
classified in the laboratory, the clinical report is created and submitted to healthcare personal 
for review and further follow-up and/or discussion with individuals and families for clinical 
use. By developing, evaluating and improving the use of sequencing technology to achieve 
this clinical utility, nurses are well-situated to change the landscape of precision healthcare 
by using sequencing to develop genomic screening tools for widespread implementation of 
population based use. Because nurses are at the forefront of patient interactions it seems 
only fitting that nurse scientists lead the charge in genomic research that can be translated 
from the bench-to-bedside and be the agent for change in health policy related to genomic 
screening recommendations worldwide.
Discussion
The development of increasingly powerful technology such as genome sequencing to 
understand and decode the human genome sequence is now having a dramatic and 
expanding impact on the ability to deliver effective and precisely targeted healthcare. Nurses 
are uniquely poised to carry out a critical role in this healthcare revolution. It is crucial that 
nurses are able to provide patients with a clear and understandable rationale for the 
therapeutic interventions dictated by genomic analysis and to counsel wisely as questions 
arise from patients and families in the course of treatment.
Based on our review of current policy, we would like to comment on two issues presented by 
the AGNC statement on opportunistic genome sequencing screening. Providing a label for a 
screening tool utilizing genome-screening technology as ‘opportunistic’ provides a negative 
connotation to testing and may be off-putting to patients when considering testing. 
Furthermore, genetic screening using sequencing may soon become routine practice and in 
fact adopted as standard of care. We recommend that the term opportunistic be restricted to 
its narrow sense use—the adventitious discovery of clinically significant information about 
one condition when sequencing is performed motivated by an effort to assign a genetic basis 
to another condition. If patients are to be educated and informed about the usefulness or lack 
thereof for genome sequencing, it should be made on an individual basis based on the 
premise of precision medicine initiatives and not on fear or negativity. The AGNC 
recommendation to not screen children for “adult-onset” diseases is challenging to 
understand or implement in its current form. There are many genetically-based conditions 
that are best addressed by early therapeutic intervention or clinical screening well prior to 
the age of 21, yet “onset” may be defined as occurring in early adulthood. These artificial 
distinctions related to “adult onset” diseases must be changed in our view, to relate to the 
point in life at which early intervention is clinically important. Clinical practice and 
scientific research in pediatrics has shown that disorders once thought to be ‘adult onset’ are 
increasingly being diagnosed in childhood (e.g., diabetes, hypertension, dyslipidemia, 
obesity), and genetic risk variants have been identified in children as young as three (Taylor, 
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Sampson, Anderson, Caldwell, & Taylor, 2012; Taylor, Sun, Hunt, & Kardia, 2010). In fact, 
the prenatal screening program in the United States has been widely successful in screening 
and treating newborns for disorders that would otherwise be undiagnosed and ultimately 
saves lives of these children. To encourage clinical scientists to ignore the possibility of 
ignoring the heritable risks for development of disorders in children simply because it has 
yet to phenotypically express would be a missed opportunity to promote health and provide 
early interventions based on the child’s individual genetic profile. Although next generation 
sequencing is currently being used in clinical trials such as in the BabySeq 
(www.genomes2people.org/babyseqproject/) and the Clinical Sequencing Exploratory 
Research (CSER) consortium (https://cser-consortium.org/) and may be useful as a 
prediagnostic tool for use in clinical care, ethical issues remain (Lantos, 2016) and the 
challenge of data analytics on approximately 6 billion base pairs using whole genome 
sequencing (Wang, Lu, & Zhao, 2015) on each individual can be daunting.
Implications for Nurses and Nurse Scientists
Current clinical usage of genome sequencing technologies is confined to circumstances in 
which there is an index of suspicion that a genetic basis exists for the clinical phenotype 
exhibited by a particular patient. A potential impact of such technologies in healthcare is the 
identification of genetically vulnerable individuals through screening programs for whom 
intervention prior to the onset of pathology can delay or prevent a pathological condition. 
Although we recognize that screening itself is imperfect, it is the first necessary step in 
confirmatory testing and diagnostics. While the cost of screening programs based on whole 
genome sequencing prohibits their current use, as the cost of genome sequencing continues 
to decrease and the number of detectable and preventable conditions increases, the crossover 
point to economic viability of this methodology is inevitable. Because nurses are educated in 
genetics/genomics it seems as if they could play a more pivotal role with hands-on 
involvement in conducting genetic screening, analyzing results, and conducting the needed 
interventions and counseling for the families. Underutilization of nurses in genetic testing 
and patient education is a missed opportunity for health professionals and their patients. 
Nurses are especially astute at performing health histories, conducting testing, and providing 
needed health promotion/risk reduction education to patients. When nurses are utilized in 
this health promotion capacity, it will expand multi-disciplinary teams to identify areas 
where we can provide education to prevent exposures to specific risks based on an 
individual’s genomic profile. Translational clinical research must capitalize on what makes 
some people with a variant phenotypically express the disease and while others do not. More 
than 70–90% of chronic diseases are multifactorial and have strong environmental 
components (Yoon, Bastian, Anderson, Collins, & Jaffe, 2014). Nurses excel in patient 
teaching and are experts in creating plans of care that focus on health promotion. Nurses 
need to be more involved in every aspect of genetic testing such as sequencing and delivery 
of results in order to provide patients with the best possible information and strategies to 
improve their health.
Current recommendations and statements by the ACMG highlight some of the pros and cons 
of using genome sequencing as a screening tool. However, nurse scientists with a 
background in genomics and/or genetic epidemiology may be expertly positioned to lead in 
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the area of genome sequencing and patient care in two very important areas. Advances in 
analytical protocols and processes for DNA sequence missense mutation variances (for 
example, MacArthur et al., 2014) and laboratory informatics linked with decision support 
(for example, Jones, Johnson, & Batstone, 2014) are moving genome sequencing to clinical 
care. These protocols will serve as the basis for screening individuals with genome 
sequencing and guide the laboratory processes and confirmatory analyses required for 
reporting results to patients in an ethical, legal and socially responsible manner via genetic 
nurse scientists and counselors. Currently, there are programs available that train nurse 
scientists in complex genomic data analysis and big data computation, including the 
National Institute of Nursing Research Big Data Bootcamp (www.ninr.nih.gov/training/
trainingopportunitiesintramural/bootcamp) and the National Heart, Lung, and Blood 
Institute Programs to Increase Diversity Among Individuals Engaged in Health-Related 
Research (PRIDE) (www.nhlbi.nih.gov/research/training/PRIDE-research-programs). These 
programs may aid in positioning attendees for work in these areas of computation of next 
generation sequencing data for clinical use. By supporting and being an integral part of 
genome sequencing screening in clinical, community and resource-poor areas, genomic 
nurse scientists and counselors will make a great contribution to reducing morbidity and 
mortality among many vulnerable and underserved populations around the world in the 
long-term.
Conclusion
In addition to the education, advocacy and counseling roles, nurses’ frequent and direct 
interactions with patients provides ample opportunity to effectively translate powerful 
genomic technologies into positive health outcomes for the American population, and other 
populations worldwide. Currently, there are training programs available that educate nurse 
scientists in complex genomic data analysis and big data computation (NINR Big Data 
Bootcamp; NINR “Precision Health: From Omics to Data Science Bootcamp; NHLBI 
PRIDE programs). These programs are important resources for nurse scientists who aspire to 
respond to the challenge of analyzing large amounts of genomic data that multi-omic 
methods bring and then using those data for development of clinical interventions. Nurses 
also play a key role in bringing the benefits of genome-sequence based screening to the 
clinic by supporting the patient in understanding how DNA sequencing based findings can 
lead to therapeutic intervention which will lead to improved health over a lifetime and 
ultimately save lives.
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FIGURE 1. 
Cost for sequencing whole genomes over time. Source: National Human Genome Research 
Institute (genome.gov/sequencingcosts).
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FIGURE 2. 
Proposed roles of clinical nursing in DNA sequencing.
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TABLE 1
Newborn Screening Protocol Variation in the 50 US States
Measure Range n (%)
Disorders screened (number) 29−57a
Bloodspot storage (time) ≥ 42 daysb 50 (100)
  0–6 monthsc 16 (32)
  8–12 monthsd 11 (22)
  1.5–5.0 years 10 (20)
  >5 yearse 8 (16)
  Not specified 5 (10)
Research allowed on spots
  No 16 (32)
  Yes 23 (43)
  Not specified/under review 12 (24)
Note. Information based on data obtained from Baby’s First Test (2015) links to Public Health Departments of each State.
aM = 43.4.
b
Includes indefinite storage.
c
Includes states that store “until testing complete.
dStorage times may be longer for positive results.
e
Includes states that store bloodspots indefinitely.
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TABLE 2
Classification Categories for Sequence Dataa
Category Definition
Pathogenic Previously reported and recognized as cause of the disorder.
Likely pathogenic Previously unreported but expected to cause the disorder.
Variant: unknown significance Previously unreported and may or may not cause the disorder.
Likely benign Previously unreported and probably not causative of disease
Benign Previously reported and is recognized as a neutral variant.
Variant of unknown
  significance—suspicious
Not known or expected to be causative of disease, but is found to be associated
  with a clinical presentation.
a
From the American College of Medical Genetics and Genomics (ACMG); see Richards et al. (2008).
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